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ABSTRACT Atrial and ventricular tachyarrhythmias
can be perpetuated by up-regulation of inward rectifier
potassium channels. Thus, it may be beneficial to block
inward rectifier channels under conditions in which
their function becomes arrhythmogenic (e.g., inherited
gain-of-function mutation channelopathies, ischemia,
and chronic and vagally mediated atrial fibrillation). We
hypothesize that the antimalarial quinoline chloroquine
exerts potent antiarrhythmic effects by interacting with
the cytoplasmic domains of Kir2.1 (IK1), Kir3.1 (IKACh),
or Kir6.2 (IKATP) and reducing inward rectifier potas-
sium currents. In isolated hearts of three different
mammalian species, intracoronary chloroquine perfu-
sion reduced fibrillatory frequency (atrial or ventricu-
lar), and effectively terminated the arrhythmia with
resumption of sinus rhythm. In patch-clamp experi-
ments chloroquine blocked IK1, IKACh, and IKATP. Com-
parative molecular modeling and ligand docking of
chloroquine in the intracellular domains of Kir2.1,
Kir3.1, and Kir6.2 suggested that chloroquine blocks or
reduces potassium flow by interacting with negatively
charged amino acids facing the ion permeation vesti-
bule of the channel in question. These results open a
novel path toward discovering antiarrhythmic pharma-
cophores that target specific residues of the cytoplas-
mic domain of inward rectifier potassium channels.—
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Inward rectifier potassium channels have been
implicated in the perpetuation of reentrant tachyar-
rhythmias in the normal or diseased heart, in humans
and in experimental models. In the ventricles, Kir2.1 is
the main pore-forming protein of the inward rectifier
potassium current IK1 (1), and Kir6.2 is the pore-
forming subunit of the ATP-sensitive potassium current
IKATP (1). In the atria, Kir3.1 and 3.4 are the pore-
forming subunits of the acetylcholine-sensitive potas-
sium current IKACh (1). Gain-of-function mutations in
Kir2.1 cause an increase in IK1 and may lead to short
QT syndrome type 3 and inducible ventricular arrhyth-
mias (2), or familial atrial fibrillation (AF) (3). In
addition, IK1 is up-regulated in chronic AF (4). The
acetylcholine-sensitive potassium current (IKACh) is
constitutively active in chronic AF (4) and is thought to
underlie vagally mediated AF (5). The ATP-sensitive
potassium current (IKATP) is activated during ischemia
or hypoxia, increasing the susceptibility of the heart to
life-threatening ventricular tachyarrhythmias (6). Al-
though still incompletely understood, there appears to
be an association between the early repolarization
syndrome, increased IKATP due to a channelopathy and
idiopathic ventricular fibrillation (VF) (7). Altogether,
the above studies suggest that blockade of inward
rectifiers under certain conditions, could offer a poten-
tially useful antiarrhythmic strategy against ventricular
and atrial tachyarrhythmias (8–10).
Structurally, inward rectifiers are closely related to
each other (1). Experiments (11–13) and numerical
simulations (11, 12, 14) showed that increasing inward
rectifier currents (i.e., IK1, IKATP, or IKACh) hyperpolar-
izes the resting membrane potential and shortens the
action potential duration, resulting in the stabilization
and acceleration of atrial and ventricular tachycardia
and fibrillation.
Chloroquine is an antimalarial quinoline that has
been used extensively in the clinic (15). It was noted in
the 1950s that chloroquine also possessed potent anti-
arrhythmic properties against ventricular and atrial
tachyarrhythmias (16). However, the precise mecha-
nism of these properties remains unknown. More re-
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cently, chloroquine was shown to block IK1 (17), IKACh
(18), and pancreatic IKATP (19). In view of such studies,
we tested the hypothesis that chloroquine also blocks
the cardiac IKATP and that chloroquine’s antiarrhyth-
mic effects in both atria and ventricles are the conse-
quence of its interaction with the cytoplasmic domains
of inward rectifier channels.
We investigated the antifibrillatory effects of 10 M
chloroquine (chloroquine blood concentration during
antimalarial treatment in humans can reach 1 to 5 M;
ref. 20) in isolated Langendorff-perfused heart models
of inward rectifier-mediated arrhythmias in three dif-
ferent mammalian species. We have used a mouse
model of ventricular tachycardia/fibrillation (VT/VF)
secondary to Kir2.1 up-regulation (17), a rabbit model
of VF due to IKATP activation (12), and a sheep-heart
model of pacing-induced, cholinergically mediated AF
(13). In addition, we integrated information at the
structural, cellular, and whole-organ levels to shed light
on the changes in tachyarrhythmia dynamics caused by
the possible interactions between chloroquine and




Adult mice, rabbits, and sheep were heparinized and anes-
thetized. The heart was rapidly excised and cannulated, then
placed in the well of a custom-made chamber maintained at
37°C. Optical mapping was carried out as described earlier
(11, 13, 21), using Di-4-ANEPPS (Sigma, St. Louis, MO, USA)
and a high-resolution CCD camera (600–1000 frames/s).
Experiments in the rabbit hearts were performed in the
presence of 40 M pinacidil (Sigma), an IKATP opener (12),
and standard cholinergic AF experiments in sheep hearts
were performed as described earlier (13), in the presence of
500 nM acetylcholine (Sigma).
Electrograms
Volume-conducted ECGs approximating lead II were re-
corded in isolated mouse and rabbit hearts using a Biopac
Systems amplifier (DA100C; Biopac Systems, Inc., Goleta, CA,
USA). For multichannel recordings of extracellular potentials
in sheep hearts, we used the NavX System (St. Jude Medical,
Little Canada, MN, USA) and a Reflexion spiral catheter (St.
Jude Medical) stitched to the epicardial surface of the left
atrial free wall. Twenty unipolar signals were acquired (sam-
pling rate, 1.2 kHz) continuously for the duration of the
experiment.
Pacing
To induce VT/VF in mouse and rabbit hearts, we used short
bursts of square pulses, 3 ms in duration, at cycle lengths
between 10 and 30 ms. For AF induction in sheep hearts, we
used tachypacing through a bipolar electrode on the epicar-
dium of the right atrium (5-ms pulses, 2 diastolic thresh-
old).
Arrhythmia analysis
We constructed phase movies of reentry and traced the
trajectory of the phase singularities, where all the phases
converge, as described previously (22). We used fast Fourier
transform (FFT) analysis on each pixel of the epicardial
optical signals to generate dominant frequency (DF) maps
(22). For electrograms recorded during AF, DFs in the range
of 4–30 Hz of 5-s unipolar voltage time-series segments were
determined with the NavX built-in module.
Patch clamping
Isolated myocytes were prepared from young guinea pigs. IK1
and IKATP (100 M pinacidil) were recorded from ventricular
cells. IKACh (1 M carbachol; Sigma) was recorded from atrial
myocytes as described previously (18). Currents were re-
corded in the whole-cell configuration. Ba2-sensitive (2 mM)
I/V relationships were constructed by plotting the currents at
the end of 1-s voltage step commands (from120 mV to20
mV, holding potential of 40 mV). For the determination of
the IC50 for IK1, IKATP, and IKACh block by chloroquine, the
fractional block of current was plotted as a function of drug
concentration ([D]), and the data were fit with the Hill
equation.
Molecular modeling
Modeling studies were based on coordinates for chloroquine
extracted from DrugBank (23), and the cytoplasmic domains
of Kir2.1 (24) (PDB ID: 1U4F), Kir3.1 (24) (PDB ID: 1U4E)
and Kir6.2 modeled onto the Kir2.1 structure. For the Kir6.2
model, the sequence of Kir6.2 was overlaid onto structure of
Kir2.1 in Coot (25). The resulting structure was refined via
simulated annealing in the crystallography and NMR system
program (26) with a solvent dielectric constant of 80. Dock-
ing simulations of all structures were performed in Autodock
4.0.1 (27), employing the genetic algorithm for 10 runs with
a population size of 150. Prior to these calculations, the
ionization of the ligands was adjusted for physiological pH.
During the calculations, the protein was held rigid, and the
ligands were allowed to flex. The resulting complexes were
ranked according to binding energy. The complex with the
lowest binding energy was further refined by slow-cooled
simulated annealing followed by minimization in crystallog-
raphy and NMR system program (26). During the simulated
annealing runs, both protein and ligand were flexible. The
complex was heated to 1000 K, then cooled to 300 K in 25-K
increments with a surrounding dielectric constant of 80.
Solvent-accessible surface areas for the complexes were cal-
culated in CCP4 Access (28). Solvent-accessible surface maps
of the complexes were calculated and displayed in PyMOL
with the APBS plug-in (PyMOL Molecular Graphics System
2008; DeLano Scientific, Palo Alto, CA, USA). The probe
radius for the maps was 1.4 Å.
Statistics
Results are reported as means  sd. ANOVA and t test were
used as appropriate. Significance was taken at P  0.05.
RESULTS
Chloroquine terminates stable high-frequency VT/VF
in the mouse heart
IK1 up-regulation leads to stable and fast reentrant
ventricular arrhythmias in a mouse model of cardiac
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specific Kir2.1 overexpression (11). Here, we examined
the effects of chloroquine on VT/VF in this mouse
model. Figure 1A presents DF maps during VT in a
representative heart in which stable, high-frequency
VT/VF was induced by a rapid pacing protocol. DF
maps were obtained in control conditions (Fig. 1A, left
panel; DF43 Hz), at 5 min after administration of 10
M chloroquine (DF30 Hz), and just before termina-
tion of arrhythmia (DF21 Hz). Figure 1B plots data
from 5 experiments. DF was normalized to that mea-
sured at VT/VF onset and displayed every minute after
the addition of chloroquine. VT/VF converted to sinus
rhythm in 5 of 5 hearts after slowing by a factor of 0.5
0.12 over a mean period of 8  5 min of continuous
intracoronary drug perfusion. The representative ECG
trace in Fig. 1C shows the sudden VT/VF termination
with conversion to sinus rhythm.
Antifibrillatory effects of chloroquine in the rabbit
heart
We also examined the effects of chloroquine on VF in
the rabbit heart in the presence of 40 M pinacidil
(IKATP opener). Figure 2A shows DF maps of a rabbit
heart in VF. The domain with fastest frequency (DFmax)
was 20 Hz before 10 M chloroquine was added. At 2
min of continuous chloroquine perfusion, the maximal
frequency was reduced to 15 Hz. At 4 min, just before
termination of arrhythmia, the frequency of arrhythmia
was 9 Hz. In 5 rabbit hearts, chloroquine reduced VF
frequency by a factor of 0.41  16. In 4 of those hearts,
the drug converted VF to sinus rhythm at 4  0.5 min
of perfusion. Figure 2B plots the time course of nor-
malized DFmax following drug perfusion onset in the 4
hearts that converted to sinus rhythm. Before termina-
Figure 1. Chloroquine terminates stable high-frequency VT/VF in the mouse heart. A) Dominant frequency maps at the onset
of pacing-induced VT (DFmax43 Hz), 5 min after 10 M chloroquine (30 Hz), and before arrhythmia termination (21 Hz).
B) Plot of normalized VT/VF DFmax in 5 mouse hearts. After the addition of 10 M chloroquine, the normalized DFmax is
displayed at 1-min intervals. VT/VF terminated in 5 of 5 mouse hearts. C) Volume conducted ECG: termination of polymorphic
VT and resumption of normal sinus rhythm.
Figure 2. Antifibrillatory effects of chloroquine in the rabbit heart. A) Dominant frequency maps at the onset of pacing-induced
VF (DFmax20 Hz, red), 2 min after 10 M chloroquine (15 Hz), and before arrhythmia termination (9 Hz). B) Plot of
normalized VF DFmax in 4 mouse hearts. After the addition of 10 M chloroquine, the normalized DFmax is displayed at 1-min
time intervals. VT/VF terminated in 4 (plotted) of 5 rabbit hearts. C) Volume conducted ECG: termination of polymorphic VT
and resumption of normal sinus rhythm.
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tion, the frequency of tachyarrhythmias decelerated by
a factor of 0.42  0.18 compared to that at onset.
Figure 2C is a representative ECG showing VF termina-
tion and resumption of normal sinus rhythm.
Chloroquine terminates cholinergic AF in the sheep
heart
We investigated the effect of chloroquine in an isolated
sheep-heart model of cholinergic AF induced by rapid
atrial pacing, in the continuous presence of 0.5 M
acetylcholine (13). Figure 3A shows DF maps from a
representative experiment. Optical and multiple-elec-
trode mapping data were obtained simultaneously. The
leftmost frame is a black-and-white snapshot of the left
atrial appendage with a 20-pole catheter secured onto
the epicardium by 5 suture points. The second frame
on the left is an optical DF map constructed during AF,
before the addition of chloroquine, at which time the
DFmax was 18.5 Hz. The third frame is the DF map
obtained 4 min after chloroquine was added to the
perfusate, with a slower DFmax (11 Hz). The rightmost
frame was obtained just before AF termination; the
DFmax decreased to 8.5 Hz. Figure 3B shows tracings of
the 20 electrogram recordings immediately before ter-
mination and on conversion to sinus rhythm. In Fig. 3C,
we have plotted the normalized frequency of the 20
simultaneous unipolar atrial electrograms. Frequency
was measured every minute during control (only the
last minute is shown), and every 0.5 min during chlo-
roquine perfusion. The numbers in red indicate the
time in the experiment at which the optical DF maps in
Fig. 3A were recorded. In Fig. 3C, AF frequency was
relatively stable at all electrode locations, but decreased
steeply on chloroquine perfusion, until termination
occurred. In Fig. 3D, we display the time course of the
normalized frequency measured in 5 sheep hearts.
Each symbol represents mean  sd data in one exper-
iment. Chloroquine decreased the AF frequency by a
factor of 0.44  0.15, leading to resumption of sinus
rhythm in the 5 hearts.
Chloroquine destabilizes rotors and terminates
fibrillation by prolonging the wavelength (WL)
To investigate the possible mechanisms of chloroquine’s
antifibrillatory effects, we returned to the transgenic
mouse heart in which we had previously demonstrated
that up-regulation of IK1 results in exceedingly stable
high-frequency rotors and VF (11). Figure 4A shows the
evolution of the rotor dynamics in a representative heart.
The upper panel is the phase map snapshot of a stable
rotor that maintained VT/VF and lasted for the duration
of the experiment, until it was terminated by cloroquine.
At the center of the map, the site at which all of the
colors converge is the phase singularity (PS), which
corresponds to the tip of the wavefront (22). The arrow
indicates the direction of rotation. The bottom panel is
an illustration of PS trajectories for 15 rotations in
each case, and respective DFs at 10 different times
during chloroquine perfusion. In control, the rotor was
Figure 3. Chloroquine terminates cho-
linergic AF in the sheep heart. A) First
panel: image of the left atrial appendage
with the 20-unipole catheter stitched on
the epicardial surface. Second panel:
DF map during AF, before chloroquine
(DFmax18.5 Hz). Third panel: DF map
at 4 min after chloroquine (DFmax11
Hz). Fourth panel: just before termina-
tion (DFmax8.5 Hz). Numbers in red
relate to panel C (see below). One-sec-
ond, single-pixel recordings are shown
under each DF map. B) Plots of the 20
electrograms in a representative example just before chloroquine terminated AF and restored sinus rhythm. C) Plot of
frequency calculated from each of the 20 unipolar atrial electrograms in one experiment. Frequency was measured every
minute before chloroquine, and every 0.5 min after chloroquine. Numbers in red indicate the time in the experiment at
which the DF maps in panel A were taken. D) Time course of normalized frequency before and during chloroquine
treatment for the 20 electrograms in the 5 sheep. Each symbol represents an experiment.
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relatively stable at 37 Hz. With time, the excursion of
the PS trajectory became wider and more intricate, and
correspondingly the DF slowed. As chloroquine perfu-
sion continued, the PS excursions increased to such an
extent that the DF decreased all the way down to 22 Hz.
Immediately thereafter, the wavefront diverged from
the center so much that it likely collided with its
wavetail or with a tissue boundary and could no longer
undergo a full rotation. VT/VF termination was imme-
diately followed by resumption of sinus rhythm. A
similar behavior was observed in 2 mouse hearts.
Possible wavefront-wavetail collisions leading to ar-
rhythmia deceleration and termination suggested that
chloroquine might have affected the WL, which is the
product of the action potential duration (APD) and
conduction velocity(CV): WL  APD  CV. We deter-
mined the effects of 10 M chloroquine in mice on
APD and CV during pacing from the apex (white
arrow), at cycle length  140 ms. In 5 experiments,
APD75 increased from 18  1.4 to 52.3  18.4 ms
(P0.05), and CV decreased from 0.68  0.09 to
0.44  0.06 m/s (P0.05; n5) (Fig. 4B, C). This
decrease could be due to direct blockade of sodium
channels, and their inactivation due to the slight mem-
brane depolarization caused by IK1 blockade. Conse-
quently, the mean WL increased from 11.8 1.9 mm to
21.4  5.5 mm; P  0.05, supporting the idea that
wavefront-wavetail collisions contributed to arrhythmia
deceleration.
Blocking efficacy of chloroquine in Kir2.1, Kir3.1,
and Kir6.2
We conducted patch-clamp experiments to examine
effects of chloroquine on IK1, IKATP, and IKACh in
ventricular and atrial myocytes. Figure 5A–C shows data
for IK1 in guinea pig ventricular myocytes. Figure 5A
shows representative current traces, in control condi-
tions and following the addition of 3 M chloroquine.
Figure 5B shows an I/V relationship for 5 cells, illustrat-
ing most importantly the chloroquine-induced reduc-
tion in the outward component of the current. Figure
5C shows that the IC50 of IK1 block by chloroquine at
60 mV is 0.69  0.09 M. Figure 5D–F presents data
for guinea pig atrial myocytes. In Fig. 5D, the current
traces at left were obtained under control conditions;
traces in the middle are IKACh currents activated by 1
M carbachol, and traces at right are currents after the
addition of chloroquine in the continuous presence of
carbachol. Figure 5E shows the I/V relationship ob-
tained from 5 cells. In Fig. 5F, the IC50 for IKACh block
was 0.38  0.04 M. Finally, Fig. 5G–I illustrates the
data for IKATP in guinea pig ventricular myocytes.
Pancreatic IKATP has been shown to be blocked by
chloroquine (19). Here, we show that the cardiac IKATP
is blocked by the drug as well. In Fig. 5G, the current
traces at left reflect control conditions; middle traces
were obtained after addition of 100 M pinacidil to
activate IKATP, and the traces at right were obtained
Figure 4. Chloroquine destabilizes rotors and terminates VF by prolonging the
wavelength. A) Top panel: phase snapshot of a rotor in a mouse heart during VT.
Arrow denotes direction of rotation. At the center of the rotor is the PS. Bottom
panel: plots of PS trajectory and corresponding DFs at 10 different time intervals
before and after the addition of 10 M chloroquine. In control conditions, DF was
37 Hz and rotor was stationary. In the presence of chloroquine, rotor became
increasingly unstable with amplified meandering of its PS as it slowed down. DF was
22 Hz just before VT termination as a result of hypermeandering of the PS
trajectory. B) Top panels: APD75 maps. Bottom panels: activation maps. Arrow
denotes stimulation site. C) APD and CV plots in 5 hearts before and after 10 M
chloroquine. APD increased from 18  1.4 to 52.3  18.4 ms; CV decreased from
0.68  0.09 to 0.44  0.06 m/s. *P  0.05.
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after the addition of 3 M chloroquine, in the presence
of pinacidil. Figure 5H shows the I/V relationship
obtained from 5 cells. In Fig. 5I, the IC50 for IKATP block
was 0.51  0.08 M.
Chloroquine interacts with residues of the
cytoplasmic domains of cardiac Inward rectifier
channels
Data suggest that chloroquine’s effect on APD is medi-
ated, in part, by its preferential ability to block IK1 (29).
Recently, it was shown that chloroquine reduces IK1 in
the outward more than the inward direction, via its
interaction with amino acids E224, F254, D255, D259,
and E299 at the cytoplasmic tail of Kir2.1 (17). As an
extension of that study, we conducted molecular mod-
eling studies on the docking of chloroquine within the
cytoplasmic domains of Kir2.1, Kir3.1, and Kir6.2. The
results revealed that chloroquine binds more effectively
to the cytoplasmic domains of Kir2.1 and Kir3.1 than to
that of Kir6.2. In Fig. 6A–C, chloroquine, depicted in
pink, appears at the center of the modeled Kir2.1
channel. The drug is suspended in an intense band of
negative charge created by the presence of the nega-
tively charged amino acids E224, D259, and E299. Of
these residues, only E224 is in a position to form
charge-charge interactions with the molecule. D259 is
very close to choloroquine, (within 4 Å), and is involved
in van der Waals interactions. E299 is located 	5 Å
from the chloroquine molecule (Fig. 6C). In addition to
E224 and the negative charge potential stabilizing the bind-
ing of chloroquine, H226 and R260 form hydrogen bonds
with the charged nitrogens of chloroquine, and F254 from 3
subunits provides a hydrophobic base for the molecule (Fig.
6C). This mode of binding blocks the channel, inhibiting the
passage of ions. In Kir3.1 (Fig. 6D–F), the negative electro-
static potential in the channel is lower than in Kir2.1 because
there are only two acidic residues contributing to the nega-
tive charged ring, D260 and E300. Because of the shift in
negative charge, chloroquine binds closer to the cytoplasmic
orifice of the channel (Fig. 6D), interacting with F255, D260,
and Q261 and only partially blocking the channel. As illus-
trated in Fig. 6G–I, Kir6.2 lacks the ring of negative charge
due to the absence of a corresponding E224 or D259. The
Figure 5. Blocking efficacy of chloroquine in different inward rectifier channels .Voltage protocol: steps from 120 mV to 20
mV. A) IK1 current traces in ventricular myocytes. B) I/V relationship from 5 cells. C) Dose-response curve of blocked IK1 at60
mV. D) Current traces in atrial myocytes in the presence of 1 M carbachol to activate IKACh. E) I/V relationship from 5 cells.
F) Dose-response curve of blocked IKACh at 60 mV. G) Current traces in ventricular myocytes in the presence of 100 M
pinacidil to activate IKATP. E) I/V relationship from 5 cells. F) Dose-response curve of blocked IKATP at 60 mV.
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respective equivalent residues for E224 and D259 in Kir6.2
are S225 and N247, which are neutral polar residues. Only
an equivalent for E299 exists, E288, which forms a hydrogen
bond with quaternary amine. The other hydrogen bonding
interactions are with T287 and T214, equivalent to H226 in
Kir2.1 (Fig. 6G–I). This causes chloroquine to bind the side
of the channel.
Chloroquine blocks the ion permeation pathways of
Kir2.1 and Kir3.1 more effectively than that of Kir6.2
Molecular modeling studies (Fig. 6) revealed that chlo-
roquine has different modes of binding to the Kir2.1,
Kir3.1, and Kir6.2 intracellular domains, depending on
the presence or absence of electronegative residues
facing the vestibule of the channel. To unveil the
consequential effects of the different interactions of
chloroquine and the respective intracellular domains
of the three different Kir channels, solvent-accessible
areas and maps were calculated (Fig. 7). The surface
maps defining the channels show that Kir2.1, Kir3.1,
and Kir6.2 each have a cavity 	26 Å in length that runs
through the center of the tetramer and a cytoplasmic
pore opening 10 Å in diameter (Fig. 7A). On chloro-
quine binding to Kir2.1, the vestibule becomes blocked,
with its depth decreasing from 28 to 10 Å, and the
opening narrows in diameter by 2.5 Å to an opening
of 7.2  7.7 Å (Fig. 7B, C). When chloroquine binds to
Kir3.1, there is no change in the depth of the vestibule,
but the opening becomes oblong (810.3 Å) (Fig.
7B, C). In Kir6.2 bound to chloroquine, there is no
change in either the opening or the length of the
Figure 6. Chloroquine interacts with residues of the cytoplasmic domains of cardiac inward rectifier channels. Ribbon structure
of each protein is shown in gray, with chloroquine as pink sticks. Images show models of the lowest energy binding of
chloroquine to Kir2.1 (A–C), Kir3.1 (D–F), and Kir6.2 (G–I). A, D, G) Longitudinal view. B, E, F) Bird’s eye view from the
cytoplasm. C, F, I) Zoomed-in view on the bound chloroquine, showing amino acids residues within 4 Å of chloroquine depicted
as sticks. Dashed lines represent hydrogen bonds.
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vestibule. In Kir6.2, chloroquine binds to the side of a
large cavity near the membrane side of the protein,
creating a pathway 	10 Å in diameter, which most
likely will not impede the passage of potassium ions
(Fig. 7B, C). Therefore, it is doubtful that chloroquine
inhibition of Kir6.2 is taking place in the cytoplasmic
domain; it could be in the transmembrane region. In
contrast, the site of chloroquine inhibition of Kir2.1
and Kir3.1 may indeed be located in the cytoplasmic
domain. Although the opening in these proteins when
bound to chloroquine is still large enough to accom-
modate a single potassium ion with a diameter of 2.66
Å or a potassium ion with half of its first hydration shell
intact (30), the fact that chloroquine can partially block
the permeation pathway in Kir3.1 and completely oc-
clude it in Kir2.1 provides evidence that these models
show the possible sites of inhibition.
DISCUSSION
Summary
We used integrative and multidisciplinary approaches
to establish how a drug’s interaction with specific
amino acids in an ion channel modify the behavior of
arrhythmias. We show for the first time that the specific
interaction of chloroquine with each of 3 types of Kir
channel at the structural level is linked to the effects of
the drug in the whole heart. We demonstrate that the
chloroquine-induced alterations of the geometries of
the IK1, IKACh, and IKATP ion permeation pathways can
translate into an increase in inward rectification, and
necessarily affect the dynamics of tachyarrhythmias.
Inward rectifier blockade by chloroquine is antifibrilla-
tory in both the atria and the ventricles, where block-
ade of Kir2.1, Kir3.1, and Kir6.2 is achieved by chloro-
quine’s ability to interact to variable degrees with
negatively charged residues within the ion permeation
pathway of the intracellular domain of the respective
channel.
Inward rectifier potassium channels are important in
the control of the rate and frequency of functional
reentry (11–13, 22). Our data suggest that agents
capable of sufficiently reducing inward rectifier potas-
sium currents (IK1, IKATP, IKACh) in scenarios where they
exert arrhythmic effects will slow the tachyarrhythmias
and may effectively cause their termination. The above
inference is based on studies and technologies that
span three different levels of integration, including
molecular modeling of the channel’s structure/func-
tion relationships, voltage-clamp analysis of the ion
channel currents and optical mapping of wave propa-
gation.
Structural considerations
Our patch-clamp and modeling data strongly suggest
that chloroquine exerts its antiarrythmic actions in part
by interacting with residues of the cytoplasmic domains
of cardiac inward rectifier channels. The lowest-energy
model is depicted in Figs. 6 and 7. For Kir6.2, the
absence of strong negative charges in the Kir6.2 chan-
nel resulted in wide variations in the binding models
for chloroquine, unlike Kir2.1 and Kir3.1, where there
Figure 7. Chloroquine blockade of the ion
permeation pathway is more effective for Kir2.1
and Kir3.1 than for Kir6.2. Images show solvent-
accessible surface maps of the intracellular
pores of Kir2.1, Kir3.1, and Kir6.2 in the pres-
ence (green) and absence (blue) of chloro-
quine. Views are oriented as in Fig. 6B, E H.
A) Surface-accessible maps of Kir 2.1, Kir3.1,
and Kir6.2 in the absence of chloroquine. Pore
openings are 10.1  10.1 Å for Kir 2.1, 11 
11Å for Kir3.1, and 10.4  10.3 Å for Kir6.2.
B) Maps calculated in the presence of bound
chloroquine. Arrows indicate significant changes
in the surface due to chloroquine. Pore openings
are 7.2 7.7 Å for Kir2.1,8 10.3 Å for Kir3.1,
and 10.4  10.3 Å for Kir6.2. C) Placement of
chloroquine (magenta sticks) within the calcu-
lated solvent accessibility surface maps. Depth of
the permeation pathway on chloroquine binding
is unchanged for Kir3.1 (26 Å) and Kir6.2 (27
Å), but is shortened from 28 to 10.5 Å for
Kir2.1.
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was a consensus between the top 4 to 6 models, and
showed similar binding rotated by 90° due to the 4-fold
symmetry within the channel. The common theme the
Kir6.2 models tested was that they showed chloroquine
binding close to the membrane side of the Ki6.2
channel interacting with S212 and E288 in multiple
ways. This may suggest that chloroquine’s binding to
Kir6.2 requires the presence of negatively charged
amino acids, but those amino acids might not only be in
the actual cytoplasmic domain; additional binding sites
deep within the internal cavity of the transmembrane
region may be present. As such, in contrast to Kir2.1
and Kir3.1, we remain somewhat uncertain as to how
chloroquine actually binds within the Kir6.2 channel.
It is known that Kir3.1 does not form homomeric
channels on the cell surface (31). Therefore, the chan-
nel responsible for IKACh is heteromeric and formed by
Kir3.1/Kir3.4. However, a crystal structure of Kir3.1/
Kir3.4 is not available. Compared to Kir3.1, which has a
ring formed by 2 electronegative residues (D260 and
E300) where chloroquine binds, Kir3.4 has an electro-
negative ring formed by E231, D266, and E306, which
are the equivalent of E224, D259, and E299 in Kir2.1.
Consequently, the mode of interaction of chloroquine
with the heteromeric Kir3.1/Kir3.4 channel may be
similar to the interaction of the drug with Kir2.1.
Further, the numerical predictions did not take into
account factors that could change the 3-dimensional
conformation and properties of the channels and/or
alter the drug-channel interactions, due to the lack of
such structural information. In this regard, it is known
that phosphatidylinositol-4,5-bisphosphate (PIP2) has
important effects on Kir channels (32, 33) and could
play a role in modulating drug-channel interactions.
Specificity considerations
Chloroquine prolongs the APD (6) by preferentially
blocking inward rectifier channels, but it also can block
IKr, INa, and ICaL in the following order of selectivity:
IK1 	 IKr 	 INa 	 ICaL (6). Nevertheless, at the dose
used in this study, chloroquine can reduce IKr, INa, and
ICaL, which may contribute somewhat to the antifibril-
latory effects of chloroquine we have observed. In two
additional experiments we performed in the sheep
heart, 1 M chloroquine terminated cholinergic AF. It
should be noted at this point that other antimalarials,
such as halofantrine, block IKr (34). We would expect
this drug to prolong APD and therefore slow the
frequency of tachyarrhythmias. However, because of
the important role played by inward rectifier channels
in controlling frequency and stability of reentry (11),
we speculate that chloroquine will be more a more
effective antifibrillatory agent due to its ability to block
such channels. Nobably, halofantrine treatment results
in a major and well-documented prolongation of the
QT interval (35). In contrast, chloroquine’s QT-pro-
longing effect is comparatively smaller with respect to
halofantrine (35, 36). Finally, we cannot determine the
specific contribution of the expected chloroquine inhi-
bition of each of the inward rectifier current types (IK1,
IKATP, and IKACh) to arrhythmia termination in the
models. For instance, it is possible that IK1 blockade
alone could terminate arrhythmias in the IKATP and
IKACh-mediated arrhythmias. Addressing this issue in
detail will require further investigation.
Clinical perspective
It has been suggested that by blocking Kir2.1 channels,
chloroquine produces lethal arrhythmias (17). For
the first time, our data demonstrate otherwise. One of
the well-known variants of the long QT syndrome, the
so-called LQT7 or Andersen-Tawil syndrome, is associ-
ated with mutations in KCNJ2, which cause dominant-
negative suppression of Kir2.1 channel function and
ventricular arrhythmias, including torsades de pointes
(37–40). However, unlike other forms of inherited
LQTS, sudden death is rarely reported in Andersen
syndrome (41).
If increasing inward rectifier currents stabilizes reen-
trant arrhythmias (11, 12, 42), then their blockade
should lead to destabilization. Our study provides def-
inite proof for that hypothesis using a clinically pre-
scribed agent. In addition, most importantly, our re-
sults provide structural biological insight at the ion
channel level into why destabilization is occurring. We
show that the chloroquine-induced alterations of the
geometries of the IK1, IKACh, and IKATP ion permeation
pathways translate into an increase in inward rectifica-
tion, and necessarily affect the tachyarrhythmia dynam-
ics.
Future directions
We submit that taking advantage of comparable knowl-
edge may be useful in the development of novel and
potentially useful antifibrillatory pharmacophores. The
chloroquine-binding models for Kir channels provide a
starting point for feasible approaches in the generation
of new therapies. Our data suggest that the binding of
chloroquine to specific sites in Kir channels affects
arrhythmia dynamics. Therefore, crystallizing and solv-
ing the high-resolution structures of the Kir2.1, Kir3.1,
and Kir6.2 complexed with chloroquine to confirm the
binding modes of the drug to the channels will be the
next step in this process. The uniqueness of the binding
sites that chloroquine occupies in the different Kir
channels may offer the chance to develop new, more
potent, and specific compounds using structure based
drug design.
Limitations
Numerical simulations do not recapitulate all aspects of
drug-channel interactions or the possible effects of
modulatory agents, such as PIP2, on Kir channels.
Crystallization and determination of the three-dimen-
sional structure of chloroquine in complex with the Kir
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channels is essential in understanding all aspects of
drug-channel interactions. Since coronary artery dis-
ease is the underlying substrate for 	80% of patients
who experience sudden cardiac death, experiments
with chloroquine in large animal models of tachyar-
rhythmias related to ischemia and/or infarction, will be
necessary to test the hypothesis that in such settings,
chloroquine is antiarrhythmic. On the other hand,
although our experiments show that chloroquine is
very effective in terminating acute cholinergic AF,
before any of these data can be translated into the
clinic, it would be crucial to test the ability of chloro-
quine to restore sinus rhythm in animal models of
chronic/persistent AF.
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